<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: thirdparty", fill: "#6082b6"},
{source: "1: thirdparty", target: "1: regulations", fill: "#6082b6"},
{source: "1: regulations", target: "1: interpretation", fill: "#6082b6"},
{source: "1: interpretation", target: "1: current regulations", fill: "#6082b6"},
{source: "1: current regulations", target: "1: policies may", fill: "#6082b6"},
{source: "1: policies may", target: "1: adversely affect governmental", fill: "#6082b6"},
{source: "1: adversely affect governmental", target: "1: thirdparty reimbursement", fill: "#6082b6"},
{source: "1: thirdparty reimbursement", target: "1: laboratory testing", fill: "#6082b6"},
{source: "1: thirdparty", target: "8: regulations", fill: "#a020f0"},
{source: "8: regulations", target: "8: policies may", fill: "#a020f0"},
{source: "8: policies may", target: "8: adverse impact on", fill: "#a020f0"},
{source: "8: regulations", target: "11: meet governmental requirements under", fill: "#c40233"},
{source: "11: meet governmental requirements under", target: "11: regulations", fill: "#c40233"},
{source: "11: regulations", target: "11: billing practices", fill: "#c40233"},
{source: "11: billing practices", target: "11: relationships", fill: "#c40233"},
{source: "11: relationships", target: "11: hospitals could lead", fill: "#c40233"},
{source: "11: hospitals could lead", target: "11: criminal penalties exclusion from participation", fill: "#c40233"},
{source: "11: criminal penalties exclusion from participation", target: "11: Medicare and Medicaid ", fill: "#c40233"},
{source: "11: Medicare and Medicaid ", target: "11: prohibitions", fill: "#c40233"},
{source: "11: prohibitions", target: "11: restrictions", fill: "#c40233"},
{source: "11: restrictions", target: "11: laboratories", fill: "#c40233"},
{source: "11: meet governmental requirements under", target: "17: comply with", fill: "#933d41"},
{source: "17: comply with", target: "17: requirements may", fill: "#933d41"},
{source: "17: requirements may", target: "17: suspension revocation", fill: "#933d41"},
{source: "17: suspension revocation", target: "17: limitation", fill: "#933d41"},
{source: "17: limitation", target: "17: laboratorys", fill: "#933d41"},
{source: "17: laboratorys", target: "17: certificate which", fill: "#933d41"},
{source: "17: certificate which", target: "17: necessary", fill: "#933d41"},
{source: "17: necessary", target: "17: well as significant fines andor criminal penalties", fill: "#933d41"},
{source: "17: comply with", target: "25: laboratories", fill: "#b666d2"},
{source: "25: laboratories", target: "25: regulations", fill: "#b666d2"},
{source: "25: regulations", target: "25: laboratory", fill: "#b666d2"},
{source: "25: laboratories", target: "31: Regulations ", fill: "#321414"},
{source: "31: Regulations ", target: "31: transactions", fill: "#321414"},
{source: "31: transactions", target: "31: health care", fill: "#321414"},
{source: "31: health care", target: "31: services issued under", fill: "#321414"},
{source: "31: services issued under", target: "31: may negatively impact", fill: "#321414"},
{source: "31: may negatively impact", target: "31: profitability", fill: "#321414"},
{source: "31: Regulations ", target: "51: Increased ", fill: "#af4035"},
{source: "51: Increased ", target: "51: competition", fill: "#af4035"},
{source: "51: competition", target: "51: price competition could", fill: "#af4035"},
{source: "51: price competition could", target: "51: adverse impact on", fill: "#af4035"},
{source: "51: adverse impact on", target: "51: net revenues", fill: "#af4035"},
{source: "51: net revenues", target: "51: profitability", fill: "#af4035"},
{source: "51: Increased ", target: "START_HERE", fill: "#af4035"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Environmental Services</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>IT Consulting and Other Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Ask for protection</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_A">Regulation A</a></td>
      <td>In the United States under the Securities Act of 1933, any offer to sell securities must either be registered with the United States Securities and Exchange Commission (SEC) or meet certain qualifications to exempt it from such registration. Regulation A (or Reg A) contains rules providing exemptions from the registration requirements, allowing some companies to use equity crowdfunding to offer and sell their securities without having to register the securities with the SEC. Regulation A offerings are intended to make access to capital possible for small and medium-sized companies that could not otherwise bear the costs of a normal SEC registration and to allow nonaccredited investors to participate in the offering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Formula_One_regulations">Formula One regulations</a></td>
      <td>The numerous Formula One regulations, made and enforced by the FIA and later the FISA, have changed dramatically since the first Formula One World Championship in 1950. This article covers the current state of F1 technical and sporting regulations, as well as the history of the technical regulations since 1950.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Radio_regulation">Radio regulation</a></td>
      <td>Radio regulation refers to the regulation and licensing of radio in international law, by individual governments, and by municipalities.\n\n\n== International regulation ==\nThe International Telecommunication Union (ITU) is a specialized agency of the United Nations (UN) that is responsible for issues that concern information and communication technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Codes,_Rules_and_Regulations">New York Codes, Rules and Regulations</a></td>
      <td>The New York Codes, Rules and Regulations (NYCRR) contains New York state rules and regulations. The NYCRR is officially compiled by the New York State Department of State's Division of Administrative Rules.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Disparate_impact">Disparate impact</a></td>
      <td>Disparate impact in United States labor law refers to practices in employment, housing, and other areas that adversely affect one group of people of a protected characteristic more than another, even though rules applied by employers or landlords are formally neutral. Although the protected classes vary by statute, most federal civil rights laws protect based on race, color, religion, national origin, and sex as protected traits, and some laws include disability status and other traits as well.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Competition_Act,_2002">The Competition Act, 2002</a></td>
      <td>The Competition Act, 2002 was enacted by the Parliament of India and governs Indian competition law. It replaced the archaic The Monopolies and Restrictive Trade Practices Act, 1969.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gang_stalking">Gang stalking</a></td>
      <td>Gang stalking or group-stalking is a set of persecutory beliefs in which those affected believe they are being followed, stalked, and harassed by a large number of people. The term is associated with the targeted individual (T.I.) virtual community formed by like-minded individuals who claim their lives are disrupted from being stalked by organized groups intent on causing them harm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Effects_of_climate_change">Effects of climate change</a></td>
      <td>The effects of climate change span the impacts on physical environment, ecosystems and human societies due to ongoing human-caused climate change. The future impact of climate change depends on how much nations reduce greenhouse gas emissions and adapt to climate change.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Thomas_Midgley_Jr.">Thomas Midgley Jr.</a></td>
      <td>Thomas Midgley Jr. (May 18, 1889 – November 2, 1944) was an American mechanical and chemical engineer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/D-8_Organization_for_Economic_Cooperation">D-8 Organization for Economic Cooperation</a></td>
      <td>The D-8 Organization for Economic Cooperation, also known as Developing-8, is an organisation for development co-operation among the following countries: Bangladesh, Egypt, Indonesia, Iran, Malaysia, Nigeria, Pakistan, and Turkey. The objectives of D-8 Organization for Economic Cooperation are to improve member states' position in the global economy, diversify and create new opportunities in trade relations, enhance participation in decision-making at international level, and improve standards of living.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adverse_possession">Adverse possession</a></td>
      <td>Adverse possession, sometimes colloquially described as "squatter's rights", is a legal principle in the Anglo-American common law under which a person who does not have legal title to a piece of property—usually land (real property)—may acquire legal ownership based on continuous possession or occupation of the property without the permission (licence) of its legal owner. The possession by a person is not adverse if they are in possession as a tenant or licensee of the legal owner.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Laboratory">Laboratory</a></td>
      <td>A laboratory (UK: ; US: ; colloquially lab) is a facility that provides controlled conditions in which scientific or technological research, experiments, and measurement may be performed. Laboratory services are provided in a variety of settings: physicians' offices, clinics, hospitals, and regional and national referral centers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Abbott_Laboratories">Abbott Laboratories</a></td>
      <td>Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Ranbaxy_Laboratories">Ranbaxy Laboratories</a></td>
      <td>Ranbaxy Laboratories Limited was an Indian multinational pharmaceutical company that was incorporated in India in 1961 and remained an entity until 2014. The company went public in 1973.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bell_Labs">Bell Labs</a></td>
      <td>Nokia Bell Labs, originally named Bell Telephone Laboratories (1925–1984),\nthen AT&amp;T Bell Laboratories (1984–1996)\nand Bell Labs Innovations (1996–2007),\nis an American industrial research and scientific development company owned by Finnish company Nokia. With headquarters located in Murray Hill, New Jersey, the company operates several laboratories in the United States and around the world.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Alkem_Laboratories">Alkem Laboratories</a></td>
      <td>Alkem Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, India that manufactures and sells pharmaceutical generics, formulations and nutraceuticals in India and globally.\n\n\n== Company ==\nAlkem set up its research and development facility for ANDA development at Taloja in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Core_Laboratories">Core Laboratories</a></td>
      <td>Core Laboratories N.V. is an American service provider of core and fluid analysis in the petroleum industry.\n\n\n== Background ==\nThe company’s specialties include basic rock properties, special core analysis, and PVT characterization of reservoir fluids.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Galson_Laboratories">Galson Laboratories</a></td>
      <td>Galson Laboratories is an industrial hygiene and indoor air quality testing company. It was founded in 1970 by Allen Galson.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Ipca_Laboratories">Ipca Laboratories</a></td>
      <td>Ipca Laboratories Limited is an Indian multinational pharmaceutical company based in Mumbai, India. \n\n\n== Background ==\nIt produces Theo bromine, Acetylthiophene, and P-Bromo Toluene as Active Pharmaceutical Ingredients (APIs).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Laboratory">The Laboratory</a></td>
      <td>"The Laboratory" is a poem and dramatic monologue by Robert Browning. The poem was first published in June 1844 in Hood's Magazine and Comic Miscellany, and later Dramatic Romances and Lyrics in 1845.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/HAL_Laboratory">HAL Laboratory</a></td>
      <td>HAL Laboratory, Inc., formerly shortened as HALKEN (derived from its native name), is a Japanese video game developer founded on 21 February 1980. While independent, it has been closely tied with Nintendo throughout its history, and is often referred to as a second-party developer for the company.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Dexter's_Laboratory">Dexter's Laboratory</a></td>
      <td>Dexter's Laboratory is an American animated television series created by Genndy Tartakovsky for Cartoon Network. It follows Dexter, a boy-genius and inventor with a hidden laboratory in his room, which he keeps secret from his parents.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profit_(economics)">Profit (economics)</a></td>
      <td>An economic profit is the difference between the revenue a  commercial entity has received from its outputs and the opportunity costs of its inputs. It equals to total revenue minus total cost, including both explicit and implicit costs.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profitability_index">Profitability index</a></td>
      <td>Profitability index (PI), also known as profit investment ratio (PIR) and value investment ratio (VIR), is the ratio of payoff to investment of a proposed project. It is a useful tool for ranking projects because it allows you to quantify the amount of value created per unit of investment.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Customer_profitability">Customer profitability</a></td>
      <td>Customer profitability (CP) is the profit the firm makes from serving a customer or customer group over a specified period of time, specifically the difference between the revenues earned from and the costs associated with the customer relationship in a specified period. According to Philip Kotler,"a profitable customer is a person, household or a company that overtime, yields a revenue stream that exceeds by an acceptable amount the company's cost stream of attracting, selling and servicing the customer."\nCalculating customer profit is an important step in understanding which customer relationships are better than others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Customer_Profitability_Analysis">Customer Profitability Analysis</a></td>
      <td>Customer Profitability Analysis (in short CPA) is a management accounting and a credit underwriting method, allowing businesses and lenders to determine the profitability of each customer or segments of customers, by attributing profits and costs to each customer separately. CPA can be applied at the individual customer level (more time consuming, but providing a better understanding of business situation) or at the level of customer aggregates / groups (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Porter's_five_forces_analysis">Porter's five forces analysis</a></td>
      <td>Porter's Five Forces Framework is a method of analysing the operating environment of a competition of a business. It draws from industrial organization (IO) economics to derive five forces that determine the competitive intensity and, therefore, the attractiveness (or lack thereof) of an industry in terms of its profitability.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Net_income">Net income</a></td>
      <td>In business and accounting, net income (also total comprehensive income, net earnings, net profit, bottom line, sales profit, or credit sales) is an entity's income minus cost of goods sold, expenses, depreciation and amortization, interest, and taxes for an accounting period.It is computed as the residual of all revenues and gains less all expenses and losses for the period, and has also been defined as the net increase in shareholders' equity that results from a company's operations. It is different from gross income, which only deducts the cost of goods sold from revenue.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Puig_(company)">Puig (company)</a></td>
      <td>Puig (Catalan pronunciation: [ˈputʃ], PUTSH) is a Spanish fashion and fragrance company founded in 1914 by Antoni Puig i Castelló in Barcelona, Catalonia, Spain, and still managed by the Puig family.\nPuig markets its products in 150 countries and is directly present in 26 of them, employing 4,472 people worldwide.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profit_and_Loss">Profit and Loss</a></td>
      <td>An income statement or profit and loss account (also referred to as a profit and loss statement (P&amp;L), statement of profit or loss, revenue statement, statement of financial performance, earnings statement, statement of earnings, operating statement, or statement of operations) is one of the financial statements of a company and shows the company's revenues and expenses during a particular period.It indicates how the revenues (also known as the “top line”) are transformed into the net income or net profit (the result after all revenues and expenses have been accounted for). The purpose of the income statement is to show managers and investors whether the company made money (profit) or lost money (loss) during the period being reported.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>LABORATORY CORP OF AMERICA HOLDINGS    Item 1A Risk Factors                                                       21  Item 1A Risk Factors                         Risks Associated with our Business       Changes  in federal, state, local and third-party payer <font color="blue">regulations</font> or     policies (or in the <font color="blue">interpretation</font> of current <font color="blue">regulations</font> or policies) may     <font color="blue"><font color="blue">adversely</font> affect <font color="blue">government</font>al</font> and third-party <font color="blue">reimbursement</font> for clinical     <font color="blue"><font color="blue">laboratory</font> testing</font></td>
    </tr>
    <tr>
      <td><font color="blue">Government  </font>payers,  such as Medicare and Medicaid, as well as     insurers, including <font color="blue"><font color="blue">managed care</font> <font color="blue">organization</font>s</font>, have increased their efforts     to control the cost, <font color="blue">utilization</font> and delivery of <font color="blue"><font color="blue">health care</font> services</font></td>
    </tr>
    <tr>
      <td><font color="blue">From     </font>time  to  time, <font color="blue">Congress </font>has considered and implemented changes in the     Medicare <font color="blue">fee schedules</font> in <font color="blue">conjunction with budgetary <font color="blue">legislation</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Further     </font><font color="blue">reductions</font> of <font color="blue">reimbursement</font> for Medicare <font color="blue">services may</font> be <font color="blue">implemented from</font>     time to time</td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement </font>for the <font color="blue">pathology services</font> component of our     business is also subject to statutory and <font color="blue">regulatory reduction</font></td>
    </tr>
    <tr>
      <td><font color="blue">Reductions     </font>in the <font color="blue">reimbursement</font> rates of other third-party <font color="blue">payers may</font> occur as well</td>
    </tr>
    <tr>
      <td>Such changes in the past have resulted in <font color="blue">reduced prices as well as added</font>     costs  and have <font color="blue">decreased test <font color="blue">utilization</font></font> for the <font color="blue">clinical <font color="blue">laboratory</font></font>     <font color="blue">industry by adding often</font> more <font color="blue">complex new regulatory</font> and <font color="blue">administrative</font>     <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Further changes in federal, state, local and third-party payer     <font color="blue">regulations</font> or <font color="blue">policies may</font> have a material <font color="blue">adverse impact on</font> our business</td>
    </tr>
    <tr>
      <td>We <font color="blue">could face <font color="blue">significant</font> monetary damages</font> and penalties and/or exclusion     from the <font color="blue">Medicare and Medicaid </font>programs if we violate <font color="blue">health care</font> anti-fraud     and <font color="blue">abuse laws</font></td>
    </tr>
    <tr>
      <td>We are subject to extensive <font color="blue"><font color="blue">government</font> regulation at</font> the federal,     state and <font color="blue">local levels</font></td>
    </tr>
    <tr>
      <td>Our failure to meet <font color="blue">government</font>al <font color="blue">requirements</font> under     these  <font color="blue">regulations</font>,  including those relating to <font color="blue">billing practices</font> and     <font color="blue">relationships</font>  with  physicians and hospitals, could lead to civil and     criminal penalties, exclusion from participation in <font color="blue">Medicare and Medicaid </font>    and possible <font color="blue">prohibitions</font> or <font color="blue">restrictions</font> on the use of our <font color="blue">laboratories</font></td>
    </tr>
    <tr>
      <td>While we believe we have structured our <font color="blue">operations</font> and <font color="blue">relationships</font> with     care in an effort to meet all statutory and regulatory <font color="blue">requirements</font>, there     is a risk that <font color="blue"><font color="blue">government</font> <font color="blue">authorities</font> might</font> take a <font color="blue">contrary position</font></td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font>occurrences, <font color="blue">regardless</font> of their outcome, could damage our reputation and     <font color="blue">adversely</font>  affect  important business <font color="blue">relationships</font> we have with third     parties</td>
    </tr>
    <tr>
      <td>Our business would be <font color="blue">harmed from</font> the loss or suspension of a license or     imposition of a fine or <font color="blue">penalties under</font>, or future changes in, the law or     <font color="blue">regulations</font> of the <font color="blue">Clinical Laboratory Improvement Amendments </font>of 1988 or     those of Medicare, Medicaid or other federal, state or <font color="blue">local agencies</font></td>
    </tr>
    <tr>
      <td>The clinical <font color="blue"><font color="blue">laboratory</font> testing</font> industry is subject to extensive     regulation,  and  many of these statutes and <font color="blue">regulations</font> have not been     <font color="blue">interpreted by</font> the courts</td>
    </tr>
    <tr>
      <td>The <font color="blue">Clinical Laboratory Improvement Amendments </font>of     1988  (“CLIA”)  extend  federal  oversight  to  virtually all clinical     <font color="blue">laboratories</font> by requiring that they be <font color="blue">certified by</font> the <font color="blue">federal <font color="blue">government</font></font>     or by a federally-approved accreditation agency</td>
    </tr>
    <tr>
      <td>The sanction for failure to     <font color="blue">comply with</font> CLIA <font color="blue">requirements</font> may be suspension, revocation or <font color="blue">limitation</font> of     a <font color="blue">laboratory</font>’s CLIA certificate, which is <font color="blue">necessary</font> to conduct business, as     well as <font color="blue">significant</font> fines and/or criminal penalties</td>
    </tr>
    <tr>
      <td>State laws may require that     <font color="blue">laboratories</font>  and/or <font color="blue">laboratory</font> personnel meet certain qualifications,     <font color="blue">specify certain quality controls</font> or require maintenance of <font color="blue">certain records</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that <font color="blue">applicable statutes</font> and <font color="blue">regulations</font> will     not be interpreted or <font color="blue">applied by</font> a prosecutorial, regulatory or judicial     authority in a manner that would <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td><font color="blue">Potential     </font>sanctions  for  violation  of  these  statutes and <font color="blue">regulations</font> include     <font color="blue">significant</font>  fines  and  the  suspension  or loss of <font color="blue">various licenses</font>,     <font color="blue">certificates</font> and authorizations, which could have a material adverse effect     on our business</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">compliance with</font> future <font color="blue">legislation</font> could     impose <font color="blue">additional</font> <font color="blue">requirements</font> on us which may be costly</td>
    </tr>
    <tr>
      <td><font color="blue">Failure  </font>to  comply  with  <font color="blue"><font color="blue">environment</font>al</font>,  health  and safety laws and     <font color="blue">regulations</font>,  including  the  federal  Occupational  Safety and Health     Administration Act and the Needlestick Safety and Prevention Act, which may     result in fines and penalties and loss of licensure, and have a material     adverse effect upon our business</td>
    </tr>
    <tr>
      <td>We are subject to licensing and <font color="blue">regulation under federal</font>, state and     <font color="blue">local laws</font> and <font color="blue">regulations</font> relating                                        (21)       _________________________________________________________________       to the protection of the <font color="blue">environment</font> and <font color="blue">human health</font> and safety, including     laws and <font color="blue">regulations</font> relating to the handling, transportation and disposal     of  medical  specimens, infectious and <font color="blue">hazardous waste</font> and <font color="blue">radioactive</font>     <font color="blue">materials as well as</font> to the safety and health of <font color="blue"><font color="blue">laboratory</font> employees</font></td>
    </tr>
    <tr>
      <td>All     of our <font color="blue">laboratories</font> are subject to applicable federal and state laws and     <font color="blue">regulations</font> relating to biohazard disposal of all <font color="blue">laboratory</font> specimens, and     we utilize outside vendors for disposal of such specimens</td>
    </tr>
    <tr>
      <td>In addition, the     federal  <font color="blue">Occupational Safety and Health Administration </font>has established     extensive  <font color="blue">requirements</font>  relating  to <font color="blue">workplace safety</font> for <font color="blue">health care</font>     employers, including clinical <font color="blue">laboratories</font>, whose workers may be exposed to     blood-borne  pathogens  such  as  HIV and the <font color="blue">hepatitis</font> B virus</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">requirements</font>, among other things, require work practice controls, protective     clothing and equipment, training, medical follow-up, vaccinations and other     <font color="blue">measures designed</font> to <font color="blue">minimize exposure</font> to, and <font color="blue">transmission</font> of, blood-borne     pathogens</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">Needlestick Safety and Prevention Act </font>requires,     among other things, that we include in our <font color="blue">safety programs</font> the <font color="blue">evaluation</font>     and  use of <font color="blue">engineering controls such as safety needles</font> if found to be     <font color="blue"><font color="blue">effective</font> at reducing</font> the risk of <font color="blue">needlestick injuries</font> in the workplace</td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> federal, state and <font color="blue">local laws</font> and <font color="blue">regulations</font>     could subject us to denial of the right to conduct business, fines, criminal     penalties and/or other <font color="blue">enforcement actions which would</font> have a material     adverse  effect  on  our business</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">compliance with</font> future     <font color="blue">legislation</font> could impose <font color="blue">additional</font> <font color="blue">requirements</font> on us which may be costly</td>
    </tr>
    <tr>
      <td><font color="blue">Regulations </font>requiring the use of “standard <font color="blue"><font color="blue">transaction</font>s</font>” for <font color="blue">health care</font>     <font color="blue">services issued under</font> HIPAA <font color="blue">may <font color="blue">negatively</font> impact</font> our <font color="blue">profitability</font> and cash     flows</td>
    </tr>
    <tr>
      <td>Pursuant to HIPAA, the Secretary of the Department of Health and     Human Services, or HHS, has issued final <font color="blue">regulations</font> designed to improve the     <font color="blue">efficiency</font> and <font color="blue"><font color="blue">effective</font>ness</font> of the <font color="blue">health care</font> system by facilitating the     <font color="blue"><font color="blue">electronic</font> exchange</font> of information in <font color="blue">certain financial</font> and <font color="blue">administrative</font>     <font color="blue"><font color="blue">transaction</font>s</font> while protecting the privacy and security of the information     exchanged</td>
    </tr>
    <tr>
      <td>HHS  <font color="blue">issued guidance on</font> July 24, 2003 stating that it will not     penalize a covered entity for post-implementation date <font color="blue"><font color="blue">transaction</font>s</font> that are     not <font color="blue">fully compliant with</font> the <font color="blue"><font color="blue">transaction</font>s</font> standards, if the covered entity     can <font color="blue">demonstrate</font> its good <font color="blue">faith efforts</font> to <font color="blue">comply with</font> the standards</td>
    </tr>
    <tr>
      <td>HHS’     stated purpose for this <font color="blue">flexible enforcement position</font> was to “<font color="blue">permit health</font>     plans to mitigate unintended adverse effects on covered entities’ cash flow     and business <font color="blue">operations</font> during the transition to the standards, as well as     on the <font color="blue">availability</font> and quality of <font color="blue">patient care</font></td>
    </tr>
    <tr>
      <td>” However, beginning <font color="blue">October     </font>1, 2005, the Center for <font color="blue">Medicare and Medicaid </font>Services no longer processes     incoming non-HIPAA-compliant <font color="blue">electronic</font> Medicare claims</td>
    </tr>
    <tr>
      <td>The  HIPAA  <font color="blue">transaction</font>  standards are complex, and subject to     <font color="blue">differences</font> in <font color="blue">interpretation</font> by payers</td>
    </tr>
    <tr>
      <td>For instance, some <font color="blue">payers may</font>     interpret  the  standards  to  require  us to <font color="blue">provide certain types</font> of     information, including <font color="blue">demographic</font> information not <font color="blue">usually provided</font> to us by     physicians</td>
    </tr>
    <tr>
      <td>As a result of inconsistent <font color="blue">application</font> of <font color="blue">transaction</font> standards     by payers or our <font color="blue">inability</font> to obtain certain billing information not usually     provided to us by physicians, we could face increased costs and <font color="blue">complexity</font>,     a temporary <font color="blue">disruption</font> in receipts and ongoing <font color="blue">reductions</font> in <font color="blue">reimbursement</font>s     and <font color="blue">net revenues</font></td>
    </tr>
    <tr>
      <td>In addition, new <font color="blue">requirements</font> for <font color="blue">additional</font> standard     <font color="blue"><font color="blue">transaction</font>s</font>, such as claims <font color="blue">attachments</font> or use of a <font color="blue">national provider</font>     identifier, could prove technically difficult, time-consuming or expensive     to implement</td>
    </tr>
    <tr>
      <td>We are working <font color="blue">closely with</font> our payers to establish acceptable     protocols for claims <font color="blue">submissions</font> and with our <font color="blue">trade association</font> and an     <font color="blue">industry coalition</font> to <font color="blue">present issues</font> and <font color="blue">problems as</font> they arise to the     <font color="blue">appropriate regulators</font> and <font color="blue">standards setting <font color="blue">organization</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with the HIPAA security <font color="blue">regulations</font> and privacy <font color="blue">regulations</font> may     increase our costs</td>
    </tr>
    <tr>
      <td><font color="blue">The HIPAA </font>privacy and security <font color="blue">regulations</font>, which became fully     <font color="blue">effective</font> in April 2003 and April 2005 respectively, establish comprehensive     <font color="blue">federal standards with respect</font> to the uses and <font color="blue"><font color="blue">disclosure</font>s</font> of protected     health information by health plans, <font color="blue">healthcare providers</font> and healthcare     <font color="blue">clearinghouses</font>,  in  addition  to  setting  standards  to  protect the     confidentiality, integrity and <font color="blue">availability</font> of <font color="blue">protected health</font> information</td>
    </tr>
    <tr>
      <td>The <font color="blue">regulations</font> establish a <font color="blue">complex regulatory framework on</font> a variety of     subjects, including:               • the <font color="blue">circumstances under which uses</font> and <font color="blue"><font color="blue">disclosure</font>s</font> of protected     health information are permitted or required without a specific     <font color="blue">authorization by</font> the patient, including but not limited to treatment                                        (22)       _________________________________________________________________       purposes, activities to obtain payments for our services, and our healthcare     <font color="blue">operations</font> activities;               • a patientapstas rights to access, amend and receive an <font color="blue">accounting</font> of     certain <font color="blue"><font color="blue">disclosure</font>s</font> of <font color="blue">protected health</font> information;               • the content of notices of <font color="blue">privacy practices</font> for <font color="blue">protected health</font>     information; and               • <font color="blue">administrative</font>, technical and <font color="blue">physical safeguards</font> required of     entities that use or receive <font color="blue">protected health</font> information</td>
    </tr>
    <tr>
      <td>We have <font color="blue">implemented policies</font> and procedures related to compliance     with the HIPAA privacy and security <font color="blue">regulations</font>, as required by law</td>
    </tr>
    <tr>
      <td>The     privacy <font color="blue">regulations</font> establish a “floor” and do not supersede state laws that     are more stringent</td>
    </tr>
    <tr>
      <td>Therefore, we are required to <font color="blue">comply with</font> both federal     privacy  <font color="blue">regulations</font>  and varying state <font color="blue">privacy laws</font></td>
    </tr>
    <tr>
      <td>In addition, for     <font color="blue">healthcare data transfers from</font> other countries relating to citizens of those     countries,  we must <font color="blue">comply with</font> the laws of those other countries</td>
    </tr>
    <tr>
      <td>The     federal privacy <font color="blue">regulations</font> restrict our ability to use or disclose patient     identifiable <font color="blue">laboratory</font> data, without patient authorization, for purposes     other  than payment, treatment or healthcare <font color="blue">operations</font> (as defined by     HIPAA), except for <font color="blue"><font color="blue">disclosure</font>s</font> for <font color="blue">various public policy purposes</font> and other     <font color="blue">permitted purposes outlined</font> in the privacy <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>The privacy and     security <font color="blue">regulations</font> provide for <font color="blue">significant</font> fines and other penalties for     wrongful  use or <font color="blue">disclosure</font> of <font color="blue">protected health</font> information, including     <font color="blue">potential civil</font> and <font color="blue">criminal fines</font> and penalties</td>
    </tr>
    <tr>
      <td><font color="blue">Although the HIPAA </font>statute     and <font color="blue">regulations</font> do not <font color="blue">expressly provide</font> for a private right of damages, we     also  could  <font color="blue">incur damages under</font> state laws to <font color="blue">private parties</font> for the     <font color="blue">wrongful use</font> or <font color="blue">disclosure</font> of <font color="blue">confidential health</font> information or other     <font color="blue">private personal</font> information</td>
    </tr>
    <tr>
      <td><font color="blue">Increased </font><font color="blue">competition</font>, including price <font color="blue">competition</font>, could have a material     <font color="blue">adverse impact on</font> our <font color="blue">net revenues</font> and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">clinical <font color="blue">laboratory</font></font> business is <font color="blue">intensely competitive both</font> in     terms of price and service</td>
    </tr>
    <tr>
      <td>Pricing of <font color="blue"><font color="blue">laboratory</font> testing</font> services is one of     the <font color="blue">significant</font> factors often used by <font color="blue">health care</font> providers and third-party     payers in selecting a <font color="blue">laboratory</font></td>
    </tr>
    <tr>
      <td>As a result of the <font color="blue">clinical <font color="blue">laboratory</font></font>     industry undergoing <font color="blue">significant</font> <font color="blue">consolidation</font>, larger <font color="blue">clinical <font color="blue">laboratory</font></font>     providers are able to increase cost efficiencies afforded by large-scale     <font color="blue">automated testing</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">consolidation</font> results in greater price <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>We may be unable to <font color="blue">increase cost efficiencies sufficiently</font>, if at all, and     as a result, our <font color="blue">net earnings</font> and <font color="blue">cash flows could</font> be <font color="blue"><font color="blue">negatively</font> impacted by</font>     such price <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue">competition</font>, including price <font color="blue">competition</font>, could have a     material <font color="blue">adverse impact on</font> our <font color="blue">net revenues</font> and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td><font color="blue">Failure  </font>to  develop, or acquire, licenses for new or improved testing     <font color="blue">technologies</font>, or our customers using new <font color="blue">technologies</font> to perform their own     tests, may limit our ability to <font color="blue">successfully</font> achieve our business strategy</td>
    </tr>
    <tr>
      <td>The clinical <font color="blue"><font color="blue">laboratory</font> testing</font> industry is subject to changing     <font color="blue">technology</font> and <font color="blue">new product introductions</font></td>
    </tr>
    <tr>
      <td>Our success in maintaining a     <font color="blue">leadership position</font> in genomic and other advanced testing <font color="blue">technologies</font> will     depend, in part, on our ability to <font color="blue">license new</font> and improved <font color="blue">technologies</font> for     early  <font color="blue">diagnosis</font>  on  favorable terms</td>
    </tr>
    <tr>
      <td>We may not be able to negotiate     acceptable  licensing  <font color="blue">arrangements</font> and we cannot be certain that such     <font color="blue">arrangements</font> will yield commercially successful diagnostic tests</td>
    </tr>
    <tr>
      <td>If we are     unable to license these <font color="blue">testing methods at competitive rates</font>, our research     and <font color="blue"><font color="blue">development</font> costs may increase as</font> a result</td>
    </tr>
    <tr>
      <td>In addition, if we are     unable  to <font color="blue">license new</font> or improved <font color="blue">technologies</font> to expand our esoteric     <font color="blue">testing <font color="blue">businesses</font></font>, our <font color="blue">testing methods may become outdated</font> when compared     with our <font color="blue">competition</font> and our <font color="blue">testing volume</font> and <font color="blue">revenue may</font> be <font color="blue">materially</font>     and <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>In addition, advances in <font color="blue">technology</font> may lead to the <font color="blue">development</font> of     more cost-<font color="blue">effective</font> point-of-care testing equipment that can be operated by     physicians or other <font color="blue">healthcare providers</font> in their offices or <font color="blue">by patients</font>     <font color="blue">themselves</font>  without  requiring  the  services of <font color="blue">freestanding clinical</font>     <font color="blue">laboratories</font></td>
    </tr>
    <tr>
      <td><font color="blue">Development </font>of such <font color="blue">technology</font> and its use by our customers     would reduce the demand for our <font color="blue"><font color="blue">laboratory</font> testing</font> services and <font color="blue">negatively</font>     impact our revenues</td>
    </tr>
    <tr>
      <td>Currently,  most clinical <font color="blue"><font color="blue">laboratory</font> testing</font> is <font color="blue">categorized as</font>     “high” or “moderate” <font color="blue">complexity</font>, and                                        (23)       _________________________________________________________________       thereby is subject to extensive and costly regulation under CLIA The cost     of <font color="blue">compliance with</font> CLIA reduces the cost <font color="blue"><font color="blue">effective</font>ness</font> for <font color="blue">most physicians</font>     to operate clinical <font color="blue">laboratories</font> in their offices, and other laws limit the     ability of physicians to have ownership in a <font color="blue">laboratory</font> and to <font color="blue">refer tests</font>     to such a <font color="blue">laboratory</font></td>
    </tr>
    <tr>
      <td>However, <font color="blue">manufacturers</font> of <font color="blue">laboratory</font> equipment and     <font color="blue">test kits could seek</font> to increase their sales by marketing point-of-care     <font color="blue">laboratory</font> equipment to physicians and <font color="blue">by selling test kits approved</font> for     home or <font color="blue">physician office use</font> to <font color="blue">both physicians</font> and patients</td>
    </tr>
    <tr>
      <td><font color="blue">Diagnostic     </font><font color="blue">tests approved</font> for home use are <font color="blue">automatically</font> deemed to be “waived” tests     under CLIA, <font color="blue">which may then</font> be performed in physician office <font color="blue">laboratories</font> as     well as <font color="blue">by patients</font> in their <font color="blue">homes with minimal regulatory oversight</font></td>
    </tr>
    <tr>
      <td><font color="blue">Other     </font><font color="blue">tests meeting certain</font> FDA <font color="blue">criteria also may</font> be classified as “waived” for     CLIA purposes</td>
    </tr>
    <tr>
      <td>The FDA has regulatory responsibility over instruments, test     kits, reagents and other devices used by clinical <font color="blue">laboratories</font> and has taken     <font color="blue">responsibility from</font> the <font color="blue">Centers for Disease Control </font>for <font color="blue">classifying</font> the     <font color="blue">complexity</font> of tests <font color="blue">for CLIA </font>purposes</td>
    </tr>
    <tr>
      <td><font color="blue">Increased </font>approval of “waived” test     <font color="blue">kits could lead</font> to <font color="blue">increased testing by physicians</font> in their offices, which     <font color="blue">could affect</font> our market for <font color="blue"><font color="blue">laboratory</font> testing</font> services and <font color="blue">negatively</font>     impact our revenues</td>
    </tr>
    <tr>
      <td>Changes in payer mix, including an increase in capitated managed-cost health     care or new national or networking <font color="blue">managed care</font> purchasing models, could     have a material <font color="blue">adverse impact on</font> our <font color="blue">net revenues</font> and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">tests ordered</font>     by a <font color="blue">single physician may</font> be billed to <font color="blue"><font color="blue">different</font> payers depending on</font> the     <font color="blue">medical benefits</font> of a <font color="blue">particular patient</font></td>
    </tr>
    <tr>
      <td><font color="blue">Increases </font>in the percentage of     <font color="blue">services billed</font> to <font color="blue">government</font> and <font color="blue"><font color="blue">managed care</font> payers could</font> have an adverse     impact  on our <font color="blue">net revenues</font></td>
    </tr>
    <tr>
      <td>For the year ended <font color="blue">December </font>31, 2005, the     percentage of <font color="blue">accessions by payer</font> was:               •         <font color="blue">private patients</font> - 2dtta4prca,               •         Medicare, Medicaid and other — 21dtta3prca,               •         <font color="blue">commercial clients</font> - 34dtta8prca and               •         <font color="blue">managed care</font> — 41dtta5prca</td>
    </tr>
    <tr>
      <td>Managed <font color="blue">care providers typically contract with</font> a limited number of     clinical <font color="blue">laboratories</font> and <font color="blue">then designate</font> the <font color="blue">laboratory</font> or <font color="blue">laboratories</font> to     be used for <font color="blue"><font color="blue">tests ordered</font> by participating physicians</font></td>
    </tr>
    <tr>
      <td>The majority of our     <font color="blue">managed care</font> testing is <font color="blue">negotiated on</font> a fee-for-service basis at a discount     from our <font color="blue">patient prices</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">discounts</font> have <font color="blue">historically</font> resulted in price     erosion and have <font color="blue">negatively</font> impacted our operating margins</td>
    </tr>
    <tr>
      <td>In addition,     <font color="blue"><font color="blue">managed care</font> <font color="blue">organization</font>s</font> have <font color="blue">used <font color="blue">capitated payment</font> contracts</font> in an     attempt to fix the cost of <font color="blue"><font color="blue">laboratory</font> testing</font> services for their enrollees</td>
    </tr>
    <tr>
      <td>Under a <font color="blue">capitated payment</font> contract, the <font color="blue">clinical <font color="blue">laboratory</font></font> and <font color="blue">managed care</font>     <font color="blue">organization</font>  agree  to  a  per member, per month payment to cover all     <font color="blue">laboratory</font> tests during the month, <font color="blue">regardless</font> of the number or cost of the     tests  actually performed</td>
    </tr>
    <tr>
      <td>Such contracts shift the risk of <font color="blue">additional</font>     testing  beyond  that <font color="blue">covered by</font> the <font color="blue">capitated payment</font> to the clinical     <font color="blue">laboratory</font></td>
    </tr>
    <tr>
      <td>Pursuant to <font color="blue">legislation</font> passed in late 2003, the percentage of     Medicare <font color="blue">beneficiaries enrolled</font> in Medicare <font color="blue">managed care</font> plans is expected     to increase</td>
    </tr>
    <tr>
      <td>For the year ended <font color="blue">December </font>31, 2005, capitated contracts     accounted for <font color="blue">approximately</font> dlra136dtta5 million, or 4dtta1prca, of our net sales</td>
    </tr>
    <tr>
      <td>Recently, <font color="blue">managed care</font> companies have announced their intention to     <font color="blue">adopt new national</font> or networking <font color="blue">managed care</font> <font color="blue">laboratory</font> services purchasing     models</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">participate</font> in these new models, it would have a     material <font color="blue">adverse impact on</font> our <font color="blue">net revenues</font> and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>In  addition,  <font color="blue">Medicare and Medicaid </font>and private insurers have     increased their efforts to control the cost, <font color="blue">utilization</font> and delivery of     <font color="blue"><font color="blue">health care</font> services</font>, including <font color="blue">clinical <font color="blue">laboratory</font></font> services</td>
    </tr>
    <tr>
      <td>Measures to     regulate <font color="blue">health care</font> delivery in general, and clinical <font color="blue">laboratories</font> in     particular, have resulted in reduced prices, added costs and decreased test     <font color="blue">utilization</font> for the <font color="blue">clinical <font color="blue">laboratory</font></font> industry by increasing <font color="blue">complexity</font>     and <font color="blue">adding new regulatory</font> and <font color="blue">administrative</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>We expect efforts to impose reduced <font color="blue">reimbursement</font>s and more <font color="blue">stringent cost</font>     controls by <font color="blue">government</font> and other payers to continue</td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot offset</font>     <font color="blue">additional</font>  <font color="blue">reductions</font>  in the payments we receive for our <font color="blue">services by</font>     reducing costs, increasing test volume and/or introducing new procedures, it     would have a                                        (24)       _________________________________________________________________       material <font color="blue">adverse impact on</font> our <font color="blue">net revenues</font> and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>A failure to obtain and retain <font color="blue">new customers</font> and <font color="blue">alliance partners</font>, or a     reduction in <font color="blue">tests ordered</font> or <font color="blue">specimens submitted by existing customers</font>,     <font color="blue">could impact</font> our ability to <font color="blue">successfully</font> grow our business</td>
    </tr>
    <tr>
      <td>To offset efforts by payers to reduce the cost and <font color="blue">utilization</font> of     <font color="blue">clinical <font color="blue">laboratory</font></font> services, we need to obtain and retain <font color="blue">new customers</font> and     <font color="blue">alliance partners</font></td>
    </tr>
    <tr>
      <td>In addition, a reduction in <font color="blue">tests ordered</font> or specimens     submitted by existing customers, without offsetting growth in our customer     base, <font color="blue">could impact</font> our ability to <font color="blue">successfully</font> grow our business and could     have a material <font color="blue">adverse impact on</font> our <font color="blue">net revenues</font> and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">compete primarily on</font> the basis of the quality of our testing, reporting and     information systems, our reputation in the <font color="blue">medical community</font>, the pricing of     our services and our ability to <font color="blue">employ qualified personnel</font></td>
    </tr>
    <tr>
      <td>Our failure to     <font color="blue">successfully</font> compete on any of these <font color="blue">factors could</font> result in the loss of     customers and a reduction in our ability to expand our <font color="blue">customer base</font></td>
    </tr>
    <tr>
      <td>In addition, we rely on developing <font color="blue">alliances with hospitals</font> to     expand our business <font color="blue">through traditional</font> and non-traditional business models</td>
    </tr>
    <tr>
      <td><font color="blue">Reference </font><font color="blue">agreements</font>, or the traditional business model, provide a means for     hospitals to outsource patient <font color="blue"><font color="blue">laboratory</font> testing</font> services that are esoteric     or complex, or that are not time critical</td>
    </tr>
    <tr>
      <td>A non-traditional business model     is where we <font color="blue">provide technical support services</font> in a variety of <font color="blue">health care</font>     settings</td>
    </tr>
    <tr>
      <td>Our ability to expand the number of <font color="blue">alliances with hospitals</font> and     maintain <font color="blue">current alliances</font>, many of which are <font color="blue">terminable on</font> short notice,     <font color="blue">could impact</font> our ability to <font color="blue">successfully</font> grow our business</td>
    </tr>
    <tr>
      <td>A failure to <font color="blue">integrate newly</font> acquired <font color="blue">businesses</font> and the costs related to     <font color="blue">such integration could</font> have a material <font color="blue">adverse impact on</font> our <font color="blue">net revenues</font>     and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">successful integration</font> of any business we may acquire in the     <font color="blue">future entails numerous risks</font>, including, <font color="blue">among others</font>:               •         loss of <font color="blue">key customers</font> or employees;               • <font color="blue">difficulty</font> in <font color="blue">consolidating redundant facilities</font> and     <font color="blue">infrastructure</font> and in <font color="blue">standardizing</font> information and other systems;               • failure to maintain the quality of services that <font color="blue">such companies</font>     have <font color="blue">historically</font> provided;               •   <font color="blue">coordination</font> of geographically-separated facilities and     workforces; and               • diversion of <font color="blue">management</font>’s attention from the day-to-day business     of our company</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that current or <font color="blue">future acquisitions</font>, if any, or     any related <font color="blue">integration efforts will</font> be successful, or that our business     will not be <font color="blue">adversely</font> affected by any <font color="blue">future acquisitions</font></td>
    </tr>
    <tr>
      <td>Even if we are     able to <font color="blue">successfully</font> integrate the <font color="blue">operations</font> of companies or <font color="blue">businesses</font> we     may acquire in the future, we may not be able to realize the benefits that     we expect to result <font color="blue">from such integration</font>, including projected <font color="blue">cost savings</font>     within the projected time frame or at all</td>
    </tr>
    <tr>
      <td>Adverse results in material <font color="blue">litigation matters could</font> have a material adverse     effect upon our business</td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  are not <font color="blue">currently involved</font> in any material legal     actions,  we  may become subject in the ordinary course of business to     material <font color="blue">legal action</font> related to, among other things, intellectual property     disputes, professional liability and employee-related matters, as well as     inquiries from <font color="blue">government</font>al agencies and <font color="blue">Medicare or Medicaid </font>carriers     <font color="blue">requesting comment on allegations</font> of <font color="blue">billing irregularities</font> that are brought     to their <font color="blue">attention through billing audits</font> or <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Legal actions     could  result in substantial <font color="blue">monetary damages as well as damage</font> to our     reputation with customers, which could have a material adverse effect upon     our business</td>
    </tr>
    <tr>
      <td>(25)       _________________________________________________________________       An <font color="blue">inability</font> to attract and retain experienced and <font color="blue">qualified personnel could</font>     <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>The loss of <font color="blue">key <font color="blue">management</font> personnel</font> or our <font color="blue">inability</font> to attract and     retain  experienced  and  qualified  <font color="blue">skilled employees at</font> our clinical     <font color="blue">laboratories</font> and research centers could <font color="blue">adversely</font> affect the business</td>
    </tr>
    <tr>
      <td>Our     success is <font color="blue">dependent</font> in part on the efforts of key members of our <font color="blue">management</font>     team</td>
    </tr>
    <tr>
      <td>Our success in maintaining our <font color="blue">leadership position</font> in genomic and     other advanced testing <font color="blue">technologies</font> will depend in part on our ability to     attract and retain <font color="blue">skilled research professionals</font></td>
    </tr>
    <tr>
      <td>In addition, the success     of  our  clinical <font color="blue">laboratories</font> also depends on employing and retaining     qualified and experienced <font color="blue">laboratory</font> professionals, including <font color="blue">specialists</font>,     who perform our clinical <font color="blue"><font color="blue">laboratory</font> testing</font> services</td>
    </tr>
    <tr>
      <td>In the future, if     <font color="blue">competition</font> for the services of these <font color="blue">professionals increases</font>, we may not be     able to continue to attract and retain <font color="blue">individuals</font> in our markets</td>
    </tr>
    <tr>
      <td>Our     revenues and <font color="blue">earnings could</font> be <font color="blue">adversely</font> affected if a <font color="blue">significant</font> number of     <font color="blue">professionals terminate</font> their <font color="blue">relationship with us</font> or <font color="blue">become unable</font> or     unwilling to continue their <font color="blue">employment</font></td>
    </tr>
    <tr>
      <td>Billing for <font color="blue">laboratory</font> services is a complex process</td>
    </tr>
    <tr>
      <td><font color="blue">Laboratories     </font>bill many <font color="blue">different</font> payers such as doctors, patients, hundreds of <font color="blue">different</font>     <font color="blue">insurance companies</font>, Medicare, Medicaid and employer groups, all of which     have <font color="blue">different</font> billing <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>We believe that our bad <font color="blue">debt expense</font>,     which was 5dtta3prca of our <font color="blue">net revenues</font> at <font color="blue">December </font>31, 2005, is the result of     non-credit related <font color="blue">issues which slow</font> the <font color="blue">billing process</font> and patients who     are unable or unwilling to pay</td>
    </tr>
    <tr>
      <td>If we are unable to maintain our days sales     <font color="blue">outstanding level</font> (“DSO”), which as of <font color="blue">December </font>31, 2005 was <font color="blue">approximately</font>     54 days, our bad <font color="blue">debt expense</font> and DSO could increase, which would have an     adverse effect on our business</td>
    </tr>
    <tr>
      <td>Failure in our information <font color="blue">technology</font> systems could <font color="blue">significant</font>ly increase     testing turn-around time or <font color="blue">billing process</font>es and otherwise disrupt our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">laboratory</font> <font color="blue">operations</font> depend, in part, on the continued and     <font color="blue">uninterrupted performance</font> of our information <font color="blue">technology</font> systems</td>
    </tr>
    <tr>
      <td><font color="blue">Despite     </font>network  security  measures  and  other <font color="blue">precautions</font> we have taken, our     information <font color="blue">technology</font> systems are <font color="blue">potentially vulnerable</font> to physical or     <font color="blue">electronic</font> break-ins, computer viruses and similar <font color="blue">disruptive problems</font></td>
    </tr>
    <tr>
      <td>In     addition, we are in the process of <font color="blue">integrating</font> the information <font color="blue">technology</font>     systems of our recently acquired <font color="blue">subsidiaries</font>, and we may experience system     failures or <font color="blue"><font color="blue">interruption</font>s as</font> a result of this process</td>
    </tr>
    <tr>
      <td>Sustained system     failures or <font color="blue">interruption</font> of our systems in one or more of our <font color="blue">laboratory</font>     <font color="blue">operations</font> could disrupt our ability to process <font color="blue">laboratory</font> requisitions,     perform testing, provide test results in a <font color="blue">timely manner</font> and/or bill the     <font color="blue">appropriate party</font></td>
    </tr>
    <tr>
      <td>Failure of our information <font color="blue">technology</font> systems could     <font color="blue">adversely</font> affect our business, <font color="blue">profitability</font> and financial condition</td>
    </tr>
    <tr>
      <td><font color="blue">Operations </font>may be disrupted and <font color="blue">adversely</font> impacted by the effects of natural     <font color="blue">disasters such as hurricanes</font> and <font color="blue">earthquakes</font>, or acts of terrorism or other     <font color="blue">criminal activities</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> may be <font color="blue">adversely</font> impacted by the effects of natural     <font color="blue">disasters such as hurricanes</font> and <font color="blue">earthquakes</font>, or acts of terrorism or other     <font color="blue">criminal activities</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">events may</font> result in a <font color="blue">temporary decline</font> in the     number of patients who seek <font color="blue"><font color="blue">laboratory</font> testing</font> services</td>
    </tr>
    <tr>
      <td>In addition, such     <font color="blue">events may</font> temporarily interrupt our ability to <font color="blue">transport specimens</font>, our     ability to utilize certain <font color="blue">laboratories</font> or to receive material from our     suppliers</td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> the Sarbanes-Oxley Act of 2002, including Section 404     of that Act which requires <font color="blue">management</font> to report on, and our in<font color="blue">dependent</font>     registered public <font color="blue">accounting</font> firm to attest to and report on, our internal     controls,  could  cause  sanctions  and  <font color="blue">investigations</font>  <font color="blue">by regulatory</font>     <font color="blue">authorities</font>, such as the SEC               If we are not able to continue to <font color="blue">comply with</font> the <font color="blue">requirements</font> of     Section 404 in a <font color="blue">timely manner</font>, our in<font color="blue">dependent</font> auditors may not be able to     <font color="blue">certify as</font> to the <font color="blue"><font color="blue">effective</font>ness</font> of our <font color="blue">internal control over financial</font>     reporting and we may be subject to sanctions or investigation <font color="blue">by regulatory</font>     <font color="blue">authorities</font>,  such  as the SEC As a result, there could be an adverse     reaction  in  the financial markets due to a loss of confidence in the     <font color="blue">reliability</font> of our <font color="blue">financial statements</font></td>
    </tr>
    <tr>
      <td>In addition, we may be required to     <font color="blue">incur costs</font> in <font color="blue">connection with continued testing</font> and <font color="blue">strengthening</font> of our     <font color="blue">internal control system</font></td>
    </tr>
  </tbody>
</table>